



MC-Rx
Powered by ProCare Rx

In-Focus

April 2021

MC-Rx's P&T Committee and team of dedicated clinicians have recommended the following changes to MC-Rx's National Formulary as of the effective dates shown. These decisions follow their clinical guidance and are based on safety, efficacy, side effect profile, and potential for abuse. While financial impact does not play a key role in the decision of coverage and preliminary placement, the ultimate cost of therapy of the selected products versus that of the other available products in the same therapeutic class is taken into consideration during final placement.

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Inhaled Osmotic Agents	Brochitol (mannitol)	Inhalation	Indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with CF	Tier 3	4/1/21
Antiretrovirals	Cabenuva (cabenuva)	Intramuscular (Specialty)	Indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per ml), on a stable antiretroviral regimen with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine	Tier 2 P/A	4/1/21
Corticosteroids (EENT)	Eysuvis (loteprednol etabonate)	Ophthalmic	Indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease	Tier 3 P/A	4/1/21
Beta ₃ Agonist	Gemtasa (vibegron)	Oral	Indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults	Tier 3	4/1/21
Anorexigenic Agents	Imcivree (setmelanotide)	Subcutaneous (Specialty)	Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)	Tier 3 P/A	4/1/21
Topical Antineoplastic Premalignant Lesion Agents	Klisyri (tirbanibulin)	Topical	Indicated for the topical treatment of actinic keratosis of the face or scalp	Tier 3 P/A	4/1/21
Immunosuppressive	Lupkynis (voclosporin)	Oral (Specialty)	Indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN)	Tier 3 P/A	4/1/21
Antigonadotropin	Orgovyx (relugolix)	Oral (Specialty)	Indicated for the treatment of adult patients with advanced prostate cancer	Tier 2 P/A	4/1/21
Complement Inhibitors	Orladeyo (berotralstat)	Oral (Specialty)	Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older	Tier 3 P/A	4/1/21
Cathartics and Laxatives	Sutab (sodium sulfate, magnesium sulfate, and potassium chloride)	Oral	Indicated for cleansing of the colon in preparation for colonoscopy in adults	Tier 2	4/1/21
Antineoplastic Agent	Tepmetko (tepotinib)	Oral (Specialty)	Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal epithelial transition (MET)	Tier 2 P/A	4/1/21

New BRAND Name Drug Additions to the Formulary

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Vasodilating Agent	Verquvo (vericiguat)	Oral	Indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure, or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%	Tier 3 P/A	4/1/21
Antiretroviral, Integrase Inhibitor (Anti-HIV)	Vocabria (cabotegravir)	Oral	Indicated in combination with Edurant (rilpivirine) for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL), on a stable antiretroviral regimen with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine	Tier 2 P/A	4/1/21
Systemic Enzyme Inhibitor	Zokinvy (lonafarnib)	Oral	Indicated in patients 12 months of age and older with a body surface area of 0.39 m ² and above	Tier 3 P/A	4/1/21

Medical Benefit

Clinical Category	Brand Name Generic Name	Route	Indications	Formulary Placement	Effective Date
Antineoplastic Agent	Danyelza	Intravenous	Indicated for the treatment of Neuroblastoma	Medical Benefit	4/1/21
Antiviral Agent	Ebanga	Intravenous	Indicated for the treatment of Zaire Ebolavirus Infection	Medical Benefit	4/1/21
Antiviral Agent	Inmazeb	Intravenous	Indicated for the treatment of Zaire Ebolavirus Infection	Medical Benefit	4/1/21
Antineoplastic Agent	Margenza	Intravenous	Indicated for the treatment of Breast Cancer	Medical Benefit	4/1/21
Oxalosis Agent	Oxlumo	Subcutaneous	Indicated for the treatment of PH1	Medical Benefit	4/1/21
Local Anesthetic	Posimir	Intravenous	Indicated for the treatment of Post-Surgical Pain	Medical Benefit	4/1/21
Antineoplastic Agent	Riabni	Intravenous	Indicated for the treatment of non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Wegener's Granulomatosis, Microscopic Polyangiitis	Medical Benefit	4/1/21
Anticonvulsant, Hydantoin	Sesquient	Intravenous	Indicated for the treatment of Status Epilepticus	Medical Benefit	4/1/21
Antiviral – RNA Polymerase Inhibitor	Veklury	Intravenous	Indicated for the treatment of Covid-19	Medical Benefit	4/1/21

Generic Releases & Updates Within the Next 90 Days

The following drugs are expected to lose their patents and become available generically within the next 90 days.

Zyclara		
Feraheme		
Nothera		
Otezla		
Lotemax Gel		
Linzess		

Additional Notes

Copies of MC-Rx's National Formulary and Pocket Formulary can be found on our website, <http://www.mc-rx.com>, under the "PBM Resources/Drug and Formulary Lists" tab.